首页|基于TREM2的抗阿尔茨海默病和缺血性脑卒中药物的药理作用研究进展

基于TREM2的抗阿尔茨海默病和缺血性脑卒中药物的药理作用研究进展

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
缺血性脑卒中(IS)和阿尔茨海默病(AD)具有共同的病理特征,如β-淀粉样蛋白沉积、血管病变、氧化应激和神经炎症等,均会导致认知能力下降.髓样细胞触发受体2(TREM2)作为免疫相关受体,可以通过调节小胶质细胞的表型和功能来协调神经炎症,参与AD和IS的进程.蛇床子素、补脾醒神益智方、AL002、褪黑激素、羟基红花黄色素A等靶向TREM2免疫受体,对AD和IS等神经退行性疾病有疗效.就TREM2在AD和IS中的重要作用和以TREM2为靶点治疗AD和IS的相关药物进行综述,以期为退行性疾病、脑血管疾病等相关治疗药物的研发提供新思路.
Research progress on pharmacological effects of anti-Alzheimer's disease and ischemic stroke drugs based on immune receptor TREM2
Alzheimer's disease(AD)and Ischemic stroke(IS)have common pathological features,such as Aβ deposition,vascular lesions,oxidative stress and neuroinflammation,which can lead to cognitive decline.Triggering receptor expressed on myeloid cells 2(TREM2),as an immune-related receptor,can coordinate neuroinflammation and participate in the process of AD and IS by regulating the phenotype and function of microglia.At present,many drugs,such as osthole,Bupi Xingshen Yizhi recipe,AL002,melatonin,hydroxysafflor yellow A,etc.,target TREM2 immune receptors and have therapeutic effects on neurodegenerative diseases such as AD and IS.In this paper,the important role of TREM2 in AD and IS and the related drugs targeting TREM2 to treat AD and IS are reviewed,so as to provide new ideas for the research and development of related drugs such as degenerative diseases and cerebrovascular diseases.

ischemic strokeAlzheimer's diseasetriggering receptor expressed on myeloid cells 2(TREM2)targeting TREM2 related drugsostholehydroxysafflor yellow A

许海英、曹玉爽、袁庆、杜鑫苑、郭莉琛、梁冰、张彤、孙锦、胡利民

展开 >

天津中医药大学中医药研究院,天津 301617

天津中医药大学组分中药国家重点实验室,天津 301617

天津中医药大学中药方剂药理学教育部重点实验室,天津 301617

缺血性脑卒中 阿尔茨海默病 髓样细胞触发受体2(TREM2) 靶向TREM2药物 蛇床子素 羟基红花黄色素A

天津市科学基金项目

21JCYBJC01260

2024

10.7501/j.issn.1674-6376.2024.01.023

药物评价研究
天津药物研究院 中国药学会

药物评价研究

CSTPCD北大核心
影响因子：1.199
ISSN：1674-6376
年,卷(期)：2024.47(1)
  • 4